HEMATOLOGY

During a Targeted Oncology case-based roundtable event, Nelson Jen An Chao, MD, discussed risk management and treatment of patients with steroid-refractory acute graft-versus-host-disease as well as chronic graft-versus-host disease.

The excitement surrounding advances and improved outcomes in very difficult-to-treat diseases is palpable. Yet the complexities of these therapies also bring their own complications.

Jeffrey S. Miller, MD, discusses the findings of a study of the Tri-Specific Killer Engager platform for the activation of natural killer cells for the treatment of refractory acute myeloid leukemia and other cancers.

The probability of minimal residual disease negativity and complete remission in patients who received hyper-CVAD with blinatumomab and inotuzumab is higher compared with hyper-CVAD and blinatumomab alone.

During a Targeted Oncology case-based roundtable event, Pashna N. Munshi, MD, discussed the case of a patient who developed maculopapular rash 22 days following hematopoietic stem cell transplantion.

During a case-based roundtable event, Matthew McKinney, MD, discussed data supporting the use of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

The FDA has granted approval to azacitidine for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia following positive phase 2 research.

Manali Kamdar, MD, MBBS, discusses the background on a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell non-Hodgkin’s lymphoma.

The FDA allows for an investigational new drug application for the start of the BEXMAB study of bexmarilimab plus standard of care therapy in various hematologic malignancies.

In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed the evolving role of stem cell transplant in hematologic malignancies as CAR T-cell therapies begin to reshape treatment landscapes.

As these new techniques evolve and we adjust conditioning regimens, induction timing and dosing levels, as well as introducing different drug combinations, we are very hopeful that we will continue to see improved outcomes for hematologic malignancies, says Guenther Koehne, MD, PhD.

Patients with chronic graft-versus-host disease who received a full series of the SARS-CoV-2 vaccine showed varied immune responses, regardless of their baseline characteristics.

The primary end point has been met in the phase 3 ADVANCE trial which evaluated the efficacy and safety of efgartigimod alfa-fcab in patients with thrombocytopenia.

Total body irradiation followed by graft-versus-host disease prophylaxis is considered a feasible and effective regimen for both adult and pediatric patients, according to phase 2 study results.

In an interview with Targeted Oncology, Robert Sackstein, MD, discussed ongoing research around the strategy of targeting the sugar coat of cancer cells to potentially aid in cancer treatment, particularly in hematologic malignancies.

The positive results from EQUTE informed the doses that will be evaluated in the phase 3 EQUATOR trial of tolizumab versus placebo in combination with corticosteroids as a first-line treatment in patients with acute graft-versus-host disease.

During a Targeted Oncology case-based roundtable event, Hetty Carraway, MD, MBA, discussed risk factors for tumor lysis syndrome and the use of prophylactic agents.

In an interview with Targeted Oncology™, Hagop M. Kantarjian, MD, discussed the evolution of the acute lymphoblastic leukemia-treatment landscape and how further changes may be soon to come.

Association between itolizumab serum concentrations and clinical response have been identified in patients with acute graft-versus-host disease treated in the phase 1b EQUATE study.

NKX101 and NKX019 showed early signs of safety and efficacy in treatment of heavily pretreated patients with acute myeloid leukemia and non-Hodgkin lymphoma.

Total body irradiation (TBI) regimen and myeloablative transplantation followed by a graft-versus-host disease (GVHD) prophylaxis regimen resulted in a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies

Based on an interim analysis of a randomized phase 2 trial, use of topical ruxolitinib showed reduced body surface area of chronic graft-versus-host disease.

In an interview with Targeted Oncology, Basem Goueli, MD, PhD, MBA, discussed the recent crackdown on PI3K inhibitors and how this drug class may fit into future treatment for hematologic malignancies as well as solid tumors.

The majority of patients treated in a phase 1 trial of belimumab used as chronic graft-vs-host-disease prophylaxis showed no evidence of the disease after 20 months of follow-up.

In the prospective, double-blind, phase 2 randomized controlled trial, in which investigators evaluated the efficacy and safety of topical ruxolitinib, a novel gene signature was identified.

In a 16 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee has voted yes to future approvals of PI3K inhibitors being supported by randomized data given observed toxicities in the drug class, research showing a detriment in OS, a narrow range between effective, and toxic doses.

During a Targeted Oncology case-based roundtable event, Matthew A. Davids, MD, MMSc, discussed key considerations for prophylaxis and the use of rasburicase in managing tumor lysis syndrome.

Magrolimab clinical trials including patients with myelodysplastic syndrome and acute myeloid leukemia may continue now that the FDA has lifted a partial clinical hold.

During a presentation, Paul G. Richardson, MD, talked about the shift from triplet combination therapies toward quadruplet combinations for the treatment of multiple myeloma.